Press Release - June 27, 2017
Heidelberg, Germany, June 27, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company’s AFM24 and AFM26 programs at the EACR-AACR-SIC 2017 Special Conference in Florence, Italy.
“With our NK-cell engagers AFM24 and AFM26 we are pursuing two preclinical programs which we believe are ideally suited to exploit NK-cell mediated cytotoxicity to fight cancer,” said Dr. Martin Treder, Chief Scientific Officer of Affimed. “Our data for both programs show a well-differentiated profile from competitor products, addressing the need for higher efficacy and better safety.”
AFM24 and AFM26 are two first-in-class tetravalent, bispecific NK-cell engagers targeting CD16A, a dominant activating receptor on NK-cells. In addition, AFM24 targets EGFR, while AFM26 binds to BCMA. Corroborating the Company’s earlier data, the studies presented at EACR-AACR-SIC 2017 provided further evidence of favorable safety profiles for both NK-cell engagers and also confirmed their ability to potently and effectively lyse tumor cells, even those with very low target expression. Furthermore, the high affinity to CD16A on NK-cells, resulting in long cell retention binding to NK-cells, and the minimal influence of serum IgG on tumor cell lysis are important differentiating factors of Affimed’s NK-cell platform compared to IgG-based monoclonal antibodies (mAbs).
In detail, AFM24 was shown to be distinguished from cetuximab in vitro and in vivo through higher potency at both high and low EGFR expression levels and in RAS mutant cells, while offering a more favorable safety profile. Single and repeat dose toxicology studies in cynomolgus monkeys demonstrated that AFM24 was well-tolerated at high doses. Further differentiating AFM24 from other therapies, no evidence of skin toxicity, a side effect commonly seen for other anti-EGFR antibodies and for tyrosine kinase inhibitors, was observed.
In addition, the Company presented further data highlighting the preclinical progress of AFM26. The NK-cell engager was able to elicit efficient tumor cell lysis in both cell lines and primary cells, even at very low BCMA expression levels. In addition, the amount of inflammatory cytokines released in vitro by cells treated with AFM26 was markedly lower than those of cells treated with a BCMA/CD3 T-cell engager. Furthermore, in contrast to approved mAb therapies such as daratumumab and elotuzumab, AFM26 did not induce NK-cell depletion in vitro.
Taken together, the results presented at EACR-AACR-SIC 2017 support the therapeutic rationale of redirecting NK-cells to tumors through bispecific tetravalent NK-cell engagers, which offers a novel mode of action addressing limitations of other therapies.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forwardlooking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341